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Background: Radiation fibrosis is not easily measurable although clinical scores have been developed for this
purpose. Biomarkers present an alternative more objective approach to quantification, and estimation in blood
provides accessible samples. We investigated if blood cytokines could be used to measure established fibrosis in
patients who have undergone radiotherapy for breast cancer.
Methods: We studied two cohorts treated by breast-conserving surgery and radiotherapy in the UK START Trial A,
one with breast fibrosis (cases) and one with no or minimal fibrosis (controls). Two candidate cytokines, plasma
connective tissue growth factor (CTGF) and serum interleukin-6 (IL6) were estimated by ELISA. Comparisons between
cases and controls used the t-test or Mann–Whitney test and associations between blood concentration and clinical
factors were assessed using the Spearman rank correlation coefficient.
Results: Seventy patients were included (26 cases, 44 controls). Mean time since radiotherapy was 9.9 years (range
8.3-12.0). No statistically significant differences between cases and controls in serum IL6 (median (IQR) 0.84 pg/ml
(0.57-1.14), 0.75 pg/ml (0.41-1.43) respectively) or plasma CTGF (331.4 pg/ml (234.8-602.9), 334.5 pg/ml (270.0-452.8)
were identified. There were no significant associations between blood cytokine concentration and age, fibrosis severity,
breast size or time since radiotherapy.
Conclusions: No significant difference in IL6 or CTGF concentrations was detected between patients with breast
fibrosis and controls with minimal or no fibrosis.
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Radiation fibrosis is a component of the clinical spec-
trum of late radiation injury occurring after curative
radiotherapy for cancer and is considered to be an im-
portant underlying cause of clinical morbidity. Radiation
fibrosis is not easily measurable or quantifiable in the
clinic which is one factor limiting the testing of effective
therapeutic strategies. The current standard for measur-
ing adverse effects of radiotherapy, including fibrosis, is
by clinical score such as Late Effects Normal Tissues —
Subjective, Objective, Management, Analytic (LENT
SOMA) scale [1]. However this type of clinical score
often encompasses complex functional endpoints [2], for* Correspondence: charlotte.westbury@thh.nhs.uk
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unless otherwise stated.which a number of underlying and uncertain pathologies
may coexist. Even a simple biological endpoint such as
fibrosis may not have direct clinical correlate, for ex-
ample although breast induration is assumed to be due
to fibrosis, oedema may be contributory. Alternative
methods which may provide a more direct and precise
estimate of fibrotic disease, include radiological imaging
or the use of biomarkers, such as the estimation of cyto-
kines in blood. Biomarker assessment can also be used
to relate clinical and molecular responses, which may
inform about the relevant molecular pathways involved in
therapeutic response [3]. Tissue is not easily accessible,
and measurement in blood provides a potential non-
invasive assessment as a substitute to tissue analysis. In
the context of radiation fibrosis, blood cytokines have
been estimated to determine patterns of cytokine release
in relation to clinical radiotherapy [4] or as a predictiveral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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ported studies investigating blood cytokines as biomarkers
of established radiation fibrosis, which would provide a
tool for quantifying fibrosis.
Following radiotherapy for breast cancer, gene expres-
sion changes at mRNA level can be detected in samples
taken months or years after the treatment course in
blood from patients with established breast fibrosis [6],
and in breast tissue [7]. Genes identified in these studies
include those encoding pro-inflammatory and pro-fibrotic
cytokines. The findings of chronic alteration of gene
expression support the hypothesis that blood cytokines
implicated in radiation fibrosis could be effective bio-
markers of radiation fibrosis. We selected two candidate
biomarkers to determine as proof of principle whether
they are altered in patients with radiation fibrosis. Inter-
leukin 6 (IL6) and connective tissue growth factor (CTGF)
were selected, as both were identified by gene expression
analysis of breast tissue [7], and are implicated in the
pathogenesis of radiation fibrosis. Furthermore IL6 and
CTGF have shown roles as biomarkers in fibrotic dis-
ease of other aetiologies, including systemic sclerosis,
idiopathic pulmonary fibrosis and liver fibrosis [8-11]. We
compared blood cytokine levels in patients with estab-
lished breast fibrosis compared to control cases with min-
imal or no fibrosis. Patients were identified from the UK
START Trial A of breast radiotherapy in which compre-
hensive prospectively collected normal tissue toxicity data
was available [12].
Methods
Ethical approval and patient selection
The UK START Trial A investigated different radiother-
apy fractionation schemes in patients receiving radio-
therapy for early breast cancer. Outcome measures for
late normal tissue injury were prospectively recorded up
to 10 years following radiotherapy using a validated clin-
ical scoring system [13,14]. Scoring was performed using
two criteria to assess fibrosis, annual clinical palpation
to assess induration, and change in photographic breast
appearance from baseline at 2 and 5 years (photographic
scores). The photographic score was an indirect measure
of fibrosis, assessing change in breast size and shape
mainly due to shrinkage and distortion.
For the purpose of the current study, 2 groups of pa-
tients defined as cases with fibrosis and controls with
minimal or no fibrosis, were selected from surviving
START Trial A patients who had undergone previous
breast conserving surgery and radiotherapy at The Royal
Marsden (RM, Sutton), the Gloucestershire Oncology
Centre (GOC, Cheltenham) or the Royal Berkshire Hos-
pital (Reading) at least 5 years previously. Patient recruit-
ment for the current study was planned primarily to be at
RM, but was extended to include the Royal BerkshireHospital and GOC (5 patients from the Royal Berkshire
Hospital were referred and registered at RM for the pur-
poses of this study). Patients with clinical and photo-
graphic scores at 2 years and beyond were included.
Patients with fibrosis were defined as having moderate
(‘quite a bit’) or marked (‘very much’) palpable indur-
ation at any time point between year 2 and the date last
seen in clinic and some (mild or marked) change in
photographic breast appearance at 2 or 5 years after ra-
diation. Control patients had no or minimal (‘a little’)
palpable induration at any time points from year 2 on-
wards and no change in photographic breast appearance
at 2 and 5 years after radiation. Additional data available
for all patients included measurements of breast length
and maximum breast depth, recorded from the treat-
ment plans on the START trial A radiotherapy form.
Patients with locally recurrent or metastatic cancer and
patients with a connective tissue disorder were excluded
from the study. The study was approved by the UCLH
Research Ethics Committee Alpha, under the protocol
‘Novel clinical biomarkers for the assessment of late
normal tissue radiation fibrosis’, and all patients gave
written informed consent to take part.
Blood collection
Patients attended the RM, Sutton or GOC, Cheltenham on
one occasion for venepuncture. Plasma and serum were ob-
tained using standard protocols, centrifuged within one hour,
and specimens were snap frozen immediately after centrifu-
gation and stored at −80°C for future analysis. Measurement
of CTGF in plasma and IL-6 in serum was carried out in
accordance with previous reports and the manufacturer’s
instructions for sample preparation for ELISA [11,15].
ELISA
Samples were analysed blinded to case control status.
Blood concentrations of IL6 and CTGF were determined
with commercially available enzyme-linked immunosorb-
ent assay (ELISA) kits, using a sandwich ELISA technique.
IL6 concentrations were determined in serum (Quantikine
HS, R&D Systems, Minneapolis) and CTGF in plasma
(USCN, Life Science Inc, Wuhan). Assays were performed
according to manufacturer’s instructions. The sensitivities
of each assay were 0.039 pg/mL for serum IL6 and and
21 pg/ml for CTGF.
Power calculations and statistical methods
A difference of 10 units in the mean blood concentra-
tions of IL6 and CTGF between cases with fibrosis and
controls with minimal or no fibrosis was considered
to be of clinical importance. Assuming a standard de-
viation of 12.5 units, and with a 5% significance level
and 80% power, it was calculated that 20 cases and 40
controls would be required. Patient and treatment
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trols using the t-test for continuous variables and the
chi-squared test or Fisher’s exact test for categorical
variables. The distribution for CTGF was near normal
so the t-test was used to compare CTGF levels. The
distribution of IL6 concentration was skewed, so me-
dians with interquartile ranges (IQR) and non-parametric
methods were used. Comparisons between groups used
the unpaired t-test or the non-parametric Mann–Whitney
test as appropriate, and associations between quantitative
variables were tested using Spearman’s rank correlation
coefficient.
Results
Patient demographics
Of the 123 eligible patients invited to participate in the
study, 72 consented. One case with a second primary
breast cancer and one control patient with metastaticTable 1 Patient and treatment characteristics of cases and co
Cases
N = 26 (%)
C
N
Age when blood sample taken 66.3 (9.4) 65
(years): Mean (SD)
Time since radiotherapy 10.2 (1.2) 9.
(years): Mean (SD)
Radiotherapy schedule
50 Gy in 25Fr 10 (38.5) 9
41.6 Gy in 13Fr 11 (42.3) 18
39 Gy in 13Fr 5 (19.2) 17
Tumour bed boost
No 3 (11.5) 3
Yes 23 (88.5) 41
Lymphatic radiotherapy
None 21 (80.8) 37
Axilla only 0 (0) 0
SCF only 5 (19.2) 6
Axilla and SCF 0 (0) 1
Adjuvant chemotherapy
No 17 (65.4) 31
Yes 9 (34.6) 13
Tamoxifen
No 2 (7.7) 7
Yes 24 (92.3) 37
SD = standard deviation.
Gy = Gray.
Fr = fractions.
SCF = supraclavicular fossa.
1p-value from chi-squared test unless otherwise indicated.
2p-value from t-test.
3Fisher’s exact test.
4chi-squared test of none versus any lymphatic radiotherapy.breast cancer were excluded as per protocol and speci-
mens from the remaining 70 patients (26 cases and 44
controls) were analysed. Mean patient age at time of
blood sampling was 65.8 years (SD 7.9, range 41.8-83.5),
and mean time since radiotherapy was 9.9 years (SD 0.9,
range 8.3-12.0). For the cases, the first recording of
moderate or marked palpable induration was reported at
a median of 4.4 years (IQR 3.0-6.4) following radiother-
apy. Treatment details including the use of a radiother-
apy boost, nodal irradiation, and adjuvant systemic
therapy are shown in Table 1.
Interleukin 6
Distributions of serum IL6 concentration in fibrosis cases
and controls are shown in Figure 1a. Serum IL6 concen-
tration was not statistically significantly different between
cases and controls (Mann–Whitney test p = 0.771). There
was no evidence of an association between serum IL6ntrols
ontrols
= 44 (%)
Total
N = 70 (%)
Comparison of cases
& controls p-value
.5 (7.0) 65.8 (7.9) 0.7202
8 (0.8) 9.9 (0.9) 0.1432
0.141
(20.4) 19 (27.1)
(40.9) 29 (41.4)
(38.6) 22 (31.4)
0.6643
(6.8) 6 (13.6)
(93.2) 64 (91.4)
0.7513,4
(84.1) 58 (82.9)
(0) 0 (0)
(13.6) 11 (15.7)
(2.3) 1 (1.4)
0.861
(70.4) 48 (65.6)
(29.5) 22 (31.4)
0.4683
(15.9) 9 (12.9)
(84.1) 61 (87.1)
ab
Figure 1 Distributions of serum interleukin 6 and plasma connective tissue growth factor. Distributions of serum IL6 (a) and plasma CTGF
(b) in 26 cases with fibrosis and 44 controls without fibrosis selected from UK START Trial A patients (SD = standard deviation, IQR = interquartile range).
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0.15, p = 0.200), as has previously been reported [16].
The distributions of serum IL6 concentration according
to highest photographic score recorded at 2 or 5 years
are shown in Figure 2a; as only 3 cases with marked
change in photographic breast appearance were re-
corded, no additional conclusions could be made for
these cases (Spearman correlation coefficient 0.05, p =
0.654). There was no significant association between
serum IL6 concentration and highest score for palpableinduration (Figure 3a; Spearman correlation coefficient
0.14, p = 0.239).
There was no evidence of an association between
serum IL6 concentration and volume of tissue irradiated,
as shown by the Spearman correlation coefficients of
0.15 (p = 0.211) and 0.18 (p = 0.135) for breast length
and maximum breast depth, respectively. There was no
statistically significant association between serum IL6
concentration and time since radiotherapy treatment
(Spearman correlation coefficient = 0.04, p = 0.719).
ab
Figure 2 Relationship of interleukin 6 and connective tissue growth factor to photographic score. Distributions of (a) serum IL6
concentration and (b) plasma CTGF concentration according to highest score for change in photographic breast appearance at 2 or 5 years. In
70 patients selected from the UK START Trial A.
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Distributions of plasma CTGF concentration in fibrosis
cases and controls are shown in Figure 1b. There was
no statistically significant difference in plasma CTGF
concentration between cases and controls (t-test p = 0.550).
The distribution of plasma CTGF according to highestphotographic score recorded at 2 or 5 years is shown in
Figure 2b; no additional conclusions could be made
about a possible association due to the few cases with
marked change in photographic breast appearance
(Spearman correlation coefficient 0.04, p = 0.740). There
was no significant association between plasma CTGF
ab
Figure 3 Relationship of interleukin 6 and connective tissue growth factor to palpable induration. Distributions of (a) serum IL6
concentration and (b) plasma CTGF concentration according to highest score for palpable induration beyond 2 years following radiotherapy. In
70 patients selected from the UK START Trial A.
Westbury et al. Radiation Oncology 2014, 9:103 Page 6 of 8
http://www.ro-journal.com/content/9/1/103
Westbury et al. Radiation Oncology 2014, 9:103 Page 7 of 8
http://www.ro-journal.com/content/9/1/103concentration and highest score for palpable indur-
ation (Figure 3b; Spearman correlation coefficient 0.10,
p = 0.430).
There was no evidence of a significant association be-
tween plasma CTGF concentration and volume of breast
irradiated as indicated by the Spearman correlation
coefficients of 0.05 (p = 0.698) and 0.19 (p = 0.120) for
breast length and maximum breast depth. There was
no statistically significant association between plasma
CTGF concentration and time since radiotherapy treat-
ment (Spearman correlation coefficient = −0.04, p = 0.766).
Discussion
This study was carried out to determine the potential
utility of CTGF and IL6 concentrations in blood for
evaluation of radiation fibrosis in a population of breast
cancer patients with prospective clinical scores of fibro-
sis. Blood levels of these two candidate cytokines were
not found to be significantly different between cases
with fibrosis of the breast and controls with minimal or
no fibrosis. This was a proof of principle study using a
case control study design as one approach to investigat-
ing this question.
Two candidate cytokines were selected as possible bio-
markers of radiation fibrosis, IL6 and CTGF. IL6, a proin-
flammatory cytokine expressed by a variety of cell types,
contributes to endothelial cell dysfunction and stimulates
leukocyte recruitment, as part of the vascular response
to radiation. Vascular injury is considered to be an im-
portant factor contributing to radiation fibrosis al-
though the exact mechanism by which it contributes to
fibrogenesis is not known [17]. In human breast tissue
previously treated with radiotherapy there is a chronic
increase in expression of pro-fibrotic cytokines and
up-regulation of networks and canonical pathways in-
volved in inflammation and oxidative stress, including
IL6 signalling [7]. CTGF has been extensively studied
in fibrotic disease, including radiation fibrosis. It is an
important growth factor in pro-fibrotic mechanisms
including extracellular matrix production, and acts
downstream of the well-characterised pro-fibrotic me-
diator transforming growth factor beta. CTGF is highly
expressed in human tissues in chronic fibrotic states,
including radiation enteritis and in the stroma of irradi-
ated human breast [7,18]. Both IL6 and CTGF are pro-
teins detectable in blood at increased levels in chronic
inflammatory and fibrotic disease.
In this study, no relationship was found between cyto-
kine level and volume of breast tissue irradiated. Tissue
volume treated may be expected to influence the magni-
tude of cytokine response but the variation in measure-
ments of breast volume may be too small to contribute to
any detectable change in values of blood cytokine levels.
For the purpose of the START Trial A, two-dimensionalmeasurements of lung and heart (although not chest wall)
incorporated into the radiotherapy treatment field were
recorded. It is recognized that the pro-fibrotic response in
non-target tissues (organs at risk) could be confounding,
and clinical measurement of fibrosis in these tissues was
not carried out. Examining lung length and maximum
lung depth encompassed by the breast tangential fields,
we did not show a significant correlation with cytokine
levels (data not shown), although the increased tissue
volume treated in the small proportion of patients who
received nodal irradiation was not estimated.
Clinical scoring may be subjective and lack reproduci-
bility. Of fifteen patients in the study who first scored
moderate/marked for palpable induration before or at
5 years after radiotherapy, and who had follow-up data
available beyond 5 years, only one third had a moderate/
marked score after 5 years, suggesting limitations of re-
producibility of clinical measurement (data not shown).
With the likely complexity of underlying pathologies
relating to the defined clinical endpoints ‘induration’ and
‘change in photographic breast appearance’, it is uncer-
tain if these clinical endpoints accurately estimate actual
fibrosis in the underlying tissue. Induration scored at
less than 5 years could have included oedema rather
than fibrosis alone.
This was a pragmatic approach to investigate the use
of blood cytokines in radiation fibrosis, using an exist-
ing database of patients enrolled within a clinical trial
with prospectively collected late toxicity scores. As in-
formation on possible confounding factors which may
influence cytokine levels such as ethnicity and diet, or
drugs such as statins and ACE inhibitors which may
modulate fibrosis was not available in the database, we
cannot exclude that these and other confounding fac-
tors exist. We did not include a control group with no
previous radiotherapy in this study given the con-
straints on number of experiments and feasibility.
Conclusions
This study shows that patients with clinically scored
breast fibrosis have no difference in blood cytokine
levels compared to patients with no or minimal fibro-
sis, after breast radiotherapy. A prospective longitu-
dinal study correlating clinical scores of normal tissue
toxicity and serial blood levels of cytokines after radio-
therapy, including a baseline measurement, may be a
more useful approach to establish the role of cytokines
as biomarkers in radiation fibrosis. Furthermore, an
approach using cytokine arrays to measure expression
of multiple, non-candidate genes could provide more
insight into the pathogenesis of fibrosis or mechanistic
information about therapy response in future inter-
ventional studies where tissue is not easily accessible
to biopsy.
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